MYX 1.51% $4.71 mayne pharma group limited

Ann: Mayne Pharma presentation at JP Morgan Healthcare Conference, page-12

  1. 166 Posts.
    lightbulb Created with Sketch. 95
    There is still work to be done; it is good that things are turning, and they needed to, but it is still a WIP. The revenue may well be $400m, but the company needs the revenue to continue to grow because the company overheads needs revenue of $400m *just* for EBITDA break even.

    If we take the 4 months we know; there's $375m revenue without a positive

    https://hotcopper.com.au/data/attachments/5879/5879514-f9ac5b9e9574d1e388682eb2eb5c87f2.jpg

    I'm a fan of the CEO - I think he is on the right track, and the team around him now have a clear vision. Think it will take more than the 1/2 yearly to tell the story. Probably another 6 months, so 3rd 1/4.

    In BPD, not sure that Nextstellis is delivering a positive run-rate, think they still need Maxwell to come in and fire. But we *need* to continue to see growth as the revenue of this product delivers the biggest benefit to the bottom line.

    Be nice to see additional costs savings as well - but that's a balance when also trying to grow product(s).






 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
(20min delay)
Last
$4.71
Change
0.070(1.51%)
Mkt cap ! $400.7M
Open High Low Value Volume
$4.67 $4.75 $4.62 $953.1K 203.6K

Buyers (Bids)

No. Vol. Price($)
1 1236 $4.71
 

Sellers (Offers)

Price($) Vol. No.
$4.72 620 1
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.